<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810888</url>
  </required_header>
  <id_info>
    <org_study_id>P50NS044283_STOP_IT</org_study_id>
    <secondary_id>2P50NS044283</secondary_id>
    <nct_id>NCT00810888</nct_id>
  </id_info>
  <brief_title>The Spot Sign for Predicting and Treating ICH Growth Study</brief_title>
  <acronym>STOP-IT</acronym>
  <official_title>The Spot Sign for Predicting and Treating Intracerebral Hemorrhage Growth Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if computed tomography angiography can predict
      which individuals with intracerebral hemorrhage will experience significant growth in the
      size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study
      will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the
      effect of rFVIIa on intracerebral hemorrhage growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral hemorrhage (ICH)—breakage of a blood vessel with bleeding in the brain—is a
      devastating form of stroke with a 40-50 percent fatality rate and no proven treatment.
      Because the majority of deaths from ICH occur within several days of the stroke,
      interventions for improving outcomes must occur early in the treatment course. Among the
      potentially modifiable determinants of ICH outcome, hematoma growth is a particularly
      attractive target for intervention and a major focus of this trial.

      The purpose of this study is to determine if an imaging test called computed tomography
      angiography (CTA) can predict which individuals with ICH will experience significant growth
      in the size of the hemorrhage. Growth of the hemorrhage can cause additional injury and may
      worsen the outcome. For individuals who are at high risk for hemorrhage growth based on CTA
      results (i.e., a positive CTA &quot;spot sign,&quot; evidence of contrast leakage within the
      hemorrhage), the study will compare the effects of a drug called recombinant activated factor
      VII (NovoSeven®) or rFVIIa with a placebo to determine which is better for reducing ICH
      growth.

      The primary goals of this trial are (1) to determine the sensitivity and specificity of the
      CTA spot sign for predicting hematoma growth; (2) to determine the feasibility of using CTA
      to identify individuals with ICH who are at high risk of hematoma growth and to select study
      participants for randomization to treatment with rFVIIa or placebo; and (3) to determine the
      rate of hematoma growth among spot-positive individuals at 24 hours—comparing individuals
      treated with rFVIIa to those treated with placebo.

      Approximately 184 persons with ICH will be enrolled in one of two study groups at 12 clinical
      sites across the United States and Canada. Participants with ICH who are determined by CTA to
      be at high risk for hemorrhage growth (CTA &quot;spot sign&quot; positive) will be randomized to
      receive either the active study medication, rFVIIa, at 80 mcg/kg, or to receive a placebo (an
      inactive substance). Participants with ICH who are determined by CTA not to be at high risk
      for hemorrhage growth (determined to be CTA &quot;spot sign&quot; negative) will be enrolled into a
      prospective observational group.

      Duration of the study for participants is approximately 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Study Subjects With Life-threatening Thromboembolic Complications</measure>
    <time_frame>through day 4 after completion of study drug administration</time_frame>
    <description>Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours.</measure>
    <time_frame>From baseline to 24 hours</time_frame>
    <description>Comparison of only the subjects with a positive spot sign with respect to a categorical measure of hematoma growth from baseline to 24 hours. the outcome of interest is the percent of subjects with hematoma growth &gt; 33% or &gt; 6 cc increase in volume, from baseline to 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Sensitivity of the Spot Sign for Predicting Hematoma Growth</measure>
    <time_frame>Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
    <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as Group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Sensitivity was estimated. Sensitivity or true positive rate is defined as, the number of strokes correctly identified as spot positive according to the &quot;gold standard&quot; / the total number of strokes identified as spot positive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Specificity of the Spot Sign for Predicting Hematoma Growth</measure>
    <time_frame>Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
    <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Specificity was estimated. Specificity or true negative rate is defined as, the number of non-spot positive (spot negative) strokes according to the &quot;gold standard&quot; / the total number of strokes identified as not spot positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes</measure>
    <time_frame>through day 4 after completion of study drug</time_frame>
    <description>Evidence of a deep venous thrombosis or an elevation of troponin within 4 days of completion of study drug administration that are not associated with ECG changes that could be related to the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score &gt;= 5</measure>
    <time_frame>90 days (+/- 7 days) from time of study enrollment</time_frame>
    <description>The modified Rankin Scale (0 is best, 5 is worst - non dead, 6 is dead) was used to define a bad outcome; categorized as a score &gt;=5 versus &lt;5. As the aim of the study was to examine the effect of rFIV!!a only the randomized groups, 1 and 2, defined as spot positive by CTA were compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA</measure>
    <time_frame>Baseline head CT scan within 5 hours, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
    <description>The CTA was originally interpreted by the site radiologist so that subjects could be identified as having a positive spot sign for eligibility for randomization. The positive spot sign is indicative that there is potential for further hemorrhagic growth and these subjects were thus eligible to be randomized to receive investigational drug or placebo. The CTA scans were subsequently assessed by the study radiologist and compared for agreement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)).</measure>
    <time_frame>24 hours (+/- 3 hours) from baseline CT scan</time_frame>
    <description>Percent change in total volume (intracerebral hemorrhage (ICH) plus intraventricular hemorrhage (IVH)) from baseline CT to 24 hour CT. Percent change is expressed as difference between 24 hour total volume and baseline total volume divided by baseline total volume, expressed as a percentage. In order to examine the effect of rFIVIIa, the randomized groups, Group 1 and Group 2 only were statistically compared.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Group 1-Recombinant activated factor VII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with ICH determined by CTA to be high risk for hemorrhage growth (&quot;spot sign&quot; positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with ICH determined by CTA to be high risk for hemorrhage growth (&quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Observation Only Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA &quot;spot sign&quot; negative) enrolled into a prospective observational group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant activated factor VII</intervention_name>
    <description>Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
    <arm_group_label>Group 1-Recombinant activated factor VII</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
    <arm_group_label>Group 2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute, spontaneous ICH (including bleeding in cerebellum) diagnosed by non-enhanced CT
             scan within five hours of symptom onset. (Time of onset is defined as the last time
             the patient was witnessed to be at baseline (i.e., subjects who have stroke symptoms
             upon awakening will be considered to have their onset at beginning of sleep)

          -  Age &gt;/= 18 years through 80 years (candidates must have had their 18th birthday, but
             not had their 81st birthday)

          -  For spot positive patients, dosing of study drug within 90 minutes of enrolling CT
             scan

        Exclusion Criteria:

          -  Time of symptom onset of ICH is unknown or more than five hours prior to baseline CT
             scan,

          -  ICH secondary to known or suspected trauma, aneurysm, vascular malformation,
             hemorrhagic conversion of ischemic stroke, venous sinus thrombosis, thrombolytic
             treatment of any condition (e.g., myocardial infarction, cerebral infarction, etc.),
             central nervous system (CNS) tumor or CNS infection

          -  Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)

          -  Serum creatinine &gt; 1.4 mg/dl (123 μmol/L). Sites that currently perform CTA as
             standard of care for ICH will follow their standard procedures regarding renal
             insufficiency.

          -  Known allergy to iodinated contrast media

          -  Intravenous or intra-arterial administration of iodinated contrast media within the
             previous 24 hours of baseline CT scan

          -  Known hereditary (e.g., hemophilia) or acquired hemorrhagic diathesis, coagulation
             factor deficiency, or anticoagulant therapy with international normalized ration (INR)
             &gt; 1.2

          -  Known or suspected thrombocytopenia (unless current platelet count documented above
             50,000 / μl)

          -  Unfractionated heparin use with abnormal partial thromboplastin time (PTT)

          -  Low-molecular weight heparin use within the previous 24 hours

          -  GPIIb/IIIa antagonist use in the previous two weeks

          -  Direct thrombin inhibitor or factor Xa inhibitor within the previous 48 hours

          -  Glasgow Coma Scale score &lt; 8 at time of proposed enrollment

          -  Pre-admission modified Rankin Scale score &gt; 2

          -  Baseline ICH volume of &lt; 0.5 cc (Hematoma volume will be estimated by local
             investigators from the baseline CT using the &quot;ABC / 2 method&quot;.)

          -  Baseline ICH volume of &gt; 90 cc

          -  Planned surgical evacuation of ICH within 24 hours of symptom onset (placement of
             intraventricular catheter is not a contraindication to study enrollment.)

          -  Evidence of acute or subacute ischemic stroke on baseline qualifying CT scan

          -  Clinical history of thromboembolism or ischemic vascular disease, including myocardial
             infarction, coronary artery bypass surgery, cardiac angina, transient ischemic attack,
             ischemic stroke, peripheral artery disease (vascular claudication), cerebral bypass
             surgery, carotid endarterectomy, deep venous thrombosis, pulmonary embolism, or
             coronary or cerebrovascular angioplasty or stenting. (Clinically silent evidence of
             old ischemia on EKG (Q waves) or CT scan (silent old infarct) will not be considered
             reasons for exclusion.)

          -  Baseline electrocardiogram shows evidence of acute cardiac ischemia (ST elevation in
             two contiguous leads, new left bundle branch block (LBBB), or ST depression)

          -  Clinical history suggestive of acute cardiac ischemia (e.g., chest pain)

          -  Abnormal baseline troponin

          -  Females of childbearing potential who are known to be pregnant and/or lactating or who
             have positive pregnancy tests on admission

          -  Advanced or terminal illness or any other condition the investigator feels would pose
             a significant hazard to the patient if rFVIIa were administered

          -  Recent (within 30 days) participation in any investigational drug or device trial or
             earlier participation in any investigational drug or device trial for which the
             duration of effect is expected to persist until the time of STOP-IT enrollment

          -  Planned withdrawal of care or comfort care measures

          -  Patient known or suspected of not being able to comply with trial protocol (e.g., due
             to alcoholism, drug dependency or psychological disorder)

          -  Informed consent cannot be obtained from the patient or legally authorized
             representative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew L. Flaherty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward C. Jauch, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Primary Emergency Medicine Investigator, Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati—Clinical Coordinating Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.STOPITSTUDY.org</url>
    <description>trial website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>December 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2018</results_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Matthew Flaherty</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>ICH</keyword>
  <keyword>computed tomography angiography</keyword>
  <keyword>CTA</keyword>
  <keyword>recombinant activated factor seven</keyword>
  <keyword>rFVIIa</keyword>
  <keyword>NovoSeven</keyword>
  <keyword>recombinant activated factor VII</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Randomized to Study Drug</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Randomized to Placebo</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - Observation Only Arm</title>
          <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT and were eligible for randomization within the clinical trial portion of the protocol. In addition 73 subjects diagnosed as &quot;Spot Negative&quot; on CT were followed prospectively with no study intervention. All 92 subjects were followed to 90 days post stroke.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Randomized to Study Drug</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Randomized to Placebo</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - Observation Only Arm</title>
          <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="13.1"/>
                    <measurement group_id="B2" value="62.4" spread="12.2"/>
                    <measurement group_id="B3" value="60.7" spread="34.7"/>
                    <measurement group_id="B4" value="61.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Rankin Score (mRS)</title>
          <description>Measure of mobility prior to stroke (0=best, 5=worst)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glasgow Coma Score/Scale (GCS)</title>
          <description>Scale to measure severity due to coma status (0=worst, 15=best)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="B2" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="B3" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="B4" value="15" lower_limit="14" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Institute of Health Stroke Scale (NIHSS) Score</title>
          <description>The National Institute of Health Stroke Scale (NIHSS) Score is a scale which measures stroke severity (0=best, 42=worst)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="3.9"/>
                    <measurement group_id="B2" value="12.1" spread="4.9"/>
                    <measurement group_id="B3" value="10.3" spread="6.2"/>
                    <measurement group_id="B4" value="10.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Stroke to Computed Tomography (CT) Scan</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158.8" spread="77.0"/>
                    <measurement group_id="B2" value="90.2" spread="49.9"/>
                    <measurement group_id="B3" value="159.8" spread="81.9"/>
                    <measurement group_id="B4" value="152.9" spread="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Stroke to Study Drug Administration</title>
          <population>The Observational group did not receive study drug so the variable &quot;Time from stroke to study drug administration&quot; is not applicable</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269.9" spread="68.3"/>
                    <measurement group_id="B2" value="181.1" spread="47.1"/>
                    <measurement group_id="B4" value="222.5" spread="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Study Subjects With Life-threatening Thromboembolic Complications</title>
        <description>Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism</description>
        <time_frame>through day 4 after completion of study drug administration</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Study Subjects With Life-threatening Thromboembolic Complications</title>
          <description>Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>not adjusted for multiple comparisons as a prior hypothesis critical value &lt;0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours.</title>
        <description>Comparison of only the subjects with a positive spot sign with respect to a categorical measure of hematoma growth from baseline to 24 hours. the outcome of interest is the percent of subjects with hematoma growth &gt; 33% or &gt; 6 cc increase in volume, from baseline to 24 hours.</description>
        <time_frame>From baseline to 24 hours</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours.</title>
          <description>Comparison of only the subjects with a positive spot sign with respect to a categorical measure of hematoma growth from baseline to 24 hours. the outcome of interest is the percent of subjects with hematoma growth &gt; 33% or &gt; 6 cc increase in volume, from baseline to 24 hours.</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only the randomized subjects will be compared</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Sensitivity of the Spot Sign for Predicting Hematoma Growth</title>
        <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as Group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Sensitivity was estimated. Sensitivity or true positive rate is defined as, the number of strokes correctly identified as spot positive according to the “gold standard” / the total number of strokes identified as spot positive</description>
        <time_frame>Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Sensitivity of the Spot Sign for Predicting Hematoma Growth</title>
          <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as Group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Sensitivity was estimated. Sensitivity or true positive rate is defined as, the number of strokes correctly identified as spot positive according to the “gold standard” / the total number of strokes identified as spot positive</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
            <param_type>Sensitivity</param_type>
            <param_value>38.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.6</ci_lower_limit>
            <ci_upper_limit>64.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Specificity of the Spot Sign for Predicting Hematoma Growth</title>
        <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Specificity was estimated. Specificity or true negative rate is defined as, the number of non-spot positive (spot negative) strokes according to the “gold standard” / the total number of strokes identified as not spot positive.</description>
        <time_frame>Baseline head CT scan within 5 hours of stroke, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>The Specificity of the Spot Sign for Predicting Hematoma Growth</title>
          <description>The outcome measure is hematoma growth. Groups 2 and 3 only will be compared as group 1 had administration of study drug which was hypothesized to reduce hematoma growth. Specificity was estimated. Specificity or true negative rate is defined as, the number of non-spot positive (spot negative) strokes according to the “gold standard” / the total number of strokes identified as not spot positive.</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group 2 and Group 3.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
            <param_type>Specificity</param_type>
            <param_value>94.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.6</ci_lower_limit>
            <ci_upper_limit>98.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes</title>
        <description>Evidence of a deep venous thrombosis or an elevation of troponin within 4 days of completion of study drug administration that are not associated with ECG changes that could be related to the study drug</description>
        <time_frame>through day 4 after completion of study drug</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Other Potentially Study Drug Related Thromboembolic Complications Such as Deep Venous Thrombosis (DVT) and Elevations in Troponin Not Associated With ECG Changes</title>
          <description>Evidence of a deep venous thrombosis or an elevation of troponin within 4 days of completion of study drug administration that are not associated with ECG changes that could be related to the study drug</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score &gt;= 5</title>
        <description>The modified Rankin Scale (0 is best, 5 is worst - non dead, 6 is dead) was used to define a bad outcome; categorized as a score &gt;=5 versus &lt;5. As the aim of the study was to examine the effect of rFIV!!a only the randomized groups, 1 and 2, defined as spot positive by CTA were compared.</description>
        <time_frame>90 days (+/- 7 days) from time of study enrollment</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Spot Positive Subjects With 90-day Outcome of Modified Rankin Scale Score &gt;= 5</title>
          <description>The modified Rankin Scale (0 is best, 5 is worst - non dead, 6 is dead) was used to define a bad outcome; categorized as a score &gt;=5 versus &lt;5. As the aim of the study was to examine the effect of rFIV!!a only the randomized groups, 1 and 2, defined as spot positive by CTA were compared.</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA</title>
        <description>The CTA was originally interpreted by the site radiologist so that subjects could be identified as having a positive spot sign for eligibility for randomization. The positive spot sign is indicative that there is potential for further hemorrhagic growth and these subjects were thus eligible to be randomized to receive investigational drug or placebo. The CTA scans were subsequently assessed by the study radiologist and compared for agreement.</description>
        <time_frame>Baseline head CT scan within 5 hours, followed by a CT angiogram. Hematoma growth determined by comparison with a head CT scan performed at 24 hours.</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Overall agreement was assessed but reported by group below.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Agreement Between the Clinical Site Radiologists and the Study Radiologist With Respect to Identification of a Positive Spot Sign or the Absence of Positive Spot Sign on CTA</title>
          <description>The CTA was originally interpreted by the site radiologist so that subjects could be identified as having a positive spot sign for eligibility for randomization. The positive spot sign is indicative that there is potential for further hemorrhagic growth and these subjects were thus eligible to be randomized to receive investigational drug or placebo. The CTA scans were subsequently assessed by the study radiologist and compared for agreement.</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Overall agreement was assessed but reported by group below.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A Kappa test of overall agreement was used</non_inferiority_desc>
            <param_type>Kappa</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>A kappa of &gt;0.75 is considered excellent agreement</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)).</title>
        <description>Percent change in total volume (intracerebral hemorrhage (ICH) plus intraventricular hemorrhage (IVH)) from baseline CT to 24 hour CT. Percent change is expressed as difference between 24 hour total volume and baseline total volume divided by baseline total volume, expressed as a percentage. In order to examine the effect of rFIVIIa, the randomized groups, Group 1 and Group 2 only were statistically compared.</description>
        <time_frame>24 hours (+/- 3 hours) from baseline CT scan</time_frame>
        <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Randomized to Study Drug</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Randomized to Placebo</title>
            <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Observation Only Arm</title>
            <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Hemorrhage Volume (Intracerebral Hemorrhage (ICH) Plus Intraventricular Hemorrhage (IVH)).</title>
          <description>Percent change in total volume (intracerebral hemorrhage (ICH) plus intraventricular hemorrhage (IVH)) from baseline CT to 24 hour CT. Percent change is expressed as difference between 24 hour total volume and baseline total volume divided by baseline total volume, expressed as a percentage. In order to examine the effect of rFIVIIa, the randomized groups, Group 1 and Group 2 only were statistically compared.</description>
          <population>The analysis population consists of 19 subjects diagnosed as &quot;Spot Positive&quot; on CT who were eligible for randomization within the clinical trial portion of the protocol, as well as 73 subjects diagnosed as &quot;Spot Negative&quot; on CT who were followed prospectively with no study intervention. Statistical comparison involves only Group1 and Group 2.</population>
          <units>Percent change from baseline to 24 hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51" lower_limit="-0.84" upper_limit="33.08"/>
                    <measurement group_id="O2" value="20.96" lower_limit="14.07" upper_limit="96.57"/>
                    <measurement group_id="O3" value="5.12" lower_limit="0.28" upper_limit="16.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groups 1 and 2 only the spot positive subjects randomized to interventional drug or placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected out to 90 days from stroke onset</time_frame>
      <desc>Adverse events and serious adverse events were defined as per clinicaltrials.gov
A case report form (CRF) was used to collect:
1. Presence, description and type of adverse events; 2. Severity (mild, moderate, severe, life-threatening, death); 3. Serious (yes, no); 4. Expected (yes, no); 5. Date/Time of onset; 6. Outcome (resolved, continuing, death); 7. Date of resolution; 8. Relation to disease; 9. Relationship to study project; 10. Action taken</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Randomized to Study Drug</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg) or a placebo .
Recombinant activated factor VII: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Randomized to Placebo</title>
          <description>Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (or determined to be CTA &quot;spot sign&quot; positive for contrast leakage within the brain hematoma) will be randomized to receive either rFVIIa at 80 mcg/kg or a placebo (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Placebo: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)</description>
        </group>
        <group group_id="E3">
          <title>Group 3 - Observation Only Arm</title>
          <description>Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA “spot sign” negative) will be enrolled into a prospective observational group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset Afib</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atreriovenous malformation (AVM)</sub_title>
                <description>One not seen on baseline imaging, one complex</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ventilator aquired pneuminia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gram negative bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY DISTRESS SECONDARY TO TRACH OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Left acute on chronic subdural hematoma</sub_title>
                <description>the term was taken directly from the adverse event CRF</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness left leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Includes &quot;seizure activity&quot; in Group 1 and &quot;possible simple partial seizure&quot; in Group 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Slurred speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Increasing mass effect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>POSSIBLE MCA VESSEL THROMBOSIS WITHOUT ISCHEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Significant expansion of ICH</sub_title>
                <description>includes &quot;EXACERBATION OF INTRACEREBRAL HEMORRHAGE&quot; in Group 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cortical vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neurologic deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>WORSENING PERIHEMATOMAL EDEMA AND INCREASING MIDLINE SHIFT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>Includes &quot;DEPRESSED MENTAL STATUS SECONDARY TO ICH/IVH&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute exacerbation of renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>O2 desats on ventilator</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <description>including one &quot;right iliofemoral DVT&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hemorrhage expansion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>PE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <description>Mild in group 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>SIADH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Distended abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <description>Group 1 due to hemorrhoids</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Generalized pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pain with catherization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Right hand PIV infultration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <description>Group1 - oral</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Ventriculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising on forearms</sub_title>
                <description>Group 1- on forearms Group 3 - on thigh</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fall from bed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELEVATED ERYTHROCYTE SEDIMENTATION RATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Elevated troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Prolonged prothrombin time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>T wave inversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Leg pain</sub_title>
                <description>Group 1 right leg Group 2 right knee Group 3 &quot;right knee arthralgia/effusion&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Right shoulder rotator cuff tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <description>Group 1 &quot;SMALL SACCULAR ANEURYSM BASILAR ARTERY&quot; and &quot;ANEURYSM LEFT INTERNAL CAROID ARTERY&quot; same subject</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Somulence</sub_title>
                <description>Group1 - increasing Group 2 - persistence</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Asymptomatic MRI DWI lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cerebral edema / hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Confused speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Difficult to arouse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Group 3 - one subject &quot;seizure post (after) arteriovenous malformation repair&quot; Group 3 - one subject &quot;SIMPLE PARTIAL SEIZURES&quot; and &quot;EXACERBATION OF SIMPLE PARTIAL SEIZURE&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Group 2 - intermittent</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <description>Group 2 -worsening</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Group1 - exacerbation in one subject</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary retension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Group1 - &quot;PLEURAL EFFUSION, ATELECTASIS&quot; Group 2 &quot;SMALL BILATERAL PLEURAL EFFUSIONS&quot;</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin breakdown / irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jane Khoury, Professor of Pediatrics</name_or_title>
      <organization>Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-2690</phone>
      <email>jane.khoury@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

